Primecap Management Company Has Cut Johnson & Johnson (JNJ) Position; CAPPED FINANCIALS IN (ITSXF) Sellers Decreased By 5.08% Their Shorts

August 17, 2017 - By Linda Rogers

Primecap Management Company decreased Johnson & Johnson (JNJ) stake by 13.82% reported in 2016Q4 SEC filing. Primecap Management Company sold 348,300 shares as Johnson & Johnson (JNJ)’s stock rose 6.85%. The Primecap Management Company holds 2.17M shares with $250.13 million value, down from 2.52 million last quarter. Johnson & Johnson now has $358.74B valuation. The stock declined 0.38% or $0.51 reaching $133.66 per share. About 335,007 shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since August 17, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.

CAPPED FINANCIALS IN (OTCMKTS:ITSXF) had a decrease of 5.08% in short interest. ITSXF’s SI was 668,400 shares in August as released by FINRA. Its down 5.08% from 704,200 shares previously. It is 0.00% or $0 reaching $26.56 per share. It is down 0.00% since August 17, 2016 and is . It has underperformed by 16.70% the S&P500.

iShares S&P/TSX Capped Financials Index Fund, formerly iShares CDN S&P/TSX Capped Financials Index Fund, seeks to provide long-term capital growth by replicating, to the extent possible, the performance of the S&P/TSX Capped Financials Index through investments in the constituent issuers of such Index. The company has market cap of $900.42 million. The Index consists of securities of Canadian financial sector issuers listed on the Toronto Stock Exchange (TSX), selected by Standard & Poor’s (S&P) using its industrial classifications and guidelines for evaluating issuer capitalization, liquidity and fundamentals. It currently has negative earnings. The Index includes stocks belonging to the S&P/TSX Financial industry sector classification, with the weight of any one firm capped at 25% of the market capitalization of the Index.

Since February 28, 2017, it had 0 buys, and 3 selling transactions for $9.95 million activity. $1.99M worth of Johnson & Johnson (NYSE:JNJ) was sold by Pruden Gary J. Another trade for 50,000 shares valued at $6.18M was sold by Duato Joaquin. 14,543 shares were sold by Kapusta Ronald A, worth $1.78M on Tuesday, February 28.

Investors sentiment increased to 0.94 in 2016 Q4. Its up 0.12, from 0.82 in 2016Q3. It is positive, as 63 investors sold JNJ shares while 834 reduced holdings. 114 funds opened positions while 731 raised stakes. 1.72 billion shares or 0.88% more from 1.71 billion shares in 2016Q3 were reported. Arvest Fincl Bank Trust Division owns 171,426 shares. Tanaka Capital reported 50 shares stake. Bartlett And stated it has 0.78% in Johnson & Johnson (NYSE:JNJ). Parsons Cap Mngmt Ri reported 2.09% stake. Randolph Co Incorporated owns 3.49% invested in Johnson & Johnson (NYSE:JNJ) for 147,881 shares. Glynn Llc invested 0.63% in Johnson & Johnson (NYSE:JNJ). Endurance Wealth Management has 0.85% invested in Johnson & Johnson (NYSE:JNJ). Geode Capital Mgmt Limited Company has 26.88 million shares for 1.44% of their portfolio. Lagoda Investment Lp invested in 0.06% or 1,395 shares. Boston Common Asset owns 1.64% invested in Johnson & Johnson (NYSE:JNJ) for 97,308 shares. National Pension holds 1.38% or 1.75M shares in its portfolio. First Personal accumulated 10,013 shares. Cannell Peter B And Company Inc reported 244,913 shares or 1.02% of all its holdings. Moreover, Guardian has 0.24% invested in Johnson & Johnson (NYSE:JNJ). Vision Mgmt Inc accumulated 6,568 shares.

Among 22 analysts covering Johnson & Johnson (NYSE:JNJ), 10 have Buy rating, 4 Sell and 8 Hold. Therefore 45% are positive. Johnson & Johnson had 60 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by UBS with “Buy” on Wednesday, October 19. Argus Research upgraded the stock to “Buy” rating in Wednesday, July 20 report. On Monday, March 14 the stock rating was upgraded by Goldman Sachs to “Neutral”. The company was maintained on Friday, June 2 by BMO Capital Markets. Jefferies maintained the stock with “Hold” rating in Tuesday, August 15 report. BMO Capital Markets maintained it with “Buy” rating and $14500 target in Tuesday, July 18 report. The rating was maintained by S&P Research with “Buy” on Wednesday, October 14. RBC Capital Markets maintained the shares of JNJ in report on Wednesday, January 25 with “Outperform” rating. The firm has “Buy” rating by Argus Research given on Wednesday, April 20. The stock has “Overweight” rating by JP Morgan on Monday, May 15.